Literature DB >> 25637054

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.

Eva Barragán1, María Carmen Chillón2, Remedios Castelló-Cros3, Nerea Marcotegui3, María Isabel Prieto2, Montserrat Hoyos4, Raffaella Pippa3, Marta Llop5, Amaia Etxabe3, José Cervera5, Gabriela Rodríguez6, Ismael Buño6, José Rifón7, Jorge Sierra4, Marcos González2, María J Calasanz8, Miguel A Sanz5, María D Odero9.   

Abstract

Entities:  

Keywords:  CIP2; acute myeloid leukemia; normal karyotype; overall survival; prognosis

Mesh：

Substances：

Year:  2015        PMID： 25637054      PMCID： PMC4420227          DOI： 10.3324/haematol.2014.118117

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.

Authors:  R Pippa; A Dominguez; D J Christensen; I Moreno-Miralles; M J Blanco-Prieto; M P Vitek; M D Odero
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

2.  PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

Authors:  I Cristóbal; L Garcia-Orti; C Cirauqui; M M Alonso; M J Calasanz; M D Odero
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

3.  Treatment of acute myeloid leukemia: are we making progress?

Authors:  Alan K Burnett
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 4.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Authors:  Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

5.  c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.

Authors:  Hui Luo; Qing Li; Julie O'Neal; Friederike Kreisel; Michelle M Le Beau; Michael H Tomasson
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

6.  CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation.

Authors:  J Wang; W Li; L Li; X Yu; J Jia; C Chen
Journal:  Int J Lab Hematol       Date:  2011-01-11       Impact factor: 2.877

7.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

8.  CIP2A is associated with human breast cancer aggressivity.

Authors:  Christophe Côme; Anni Laine; Maïa Chanrion; Henrik Edgren; Elina Mattila; Xiaoling Liu; Jos Jonkers; Johanna Ivaska; Jorma Isola; Jean-Marie Darbon; Olli Kallioniemi; Simon Thézenas; Jukka Westermarck
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?

Authors:  Jay P Patel; Ross L Levine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

10.  Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Authors:  Anni Laine; Harri Sihto; Christophe Come; Mathias T Rosenfeldt; Aleksandra Zwolinska; Minna Niemelä; Anchit Khanna; Edward K Chan; Veli-Matti Kähäri; Pirkko-Liisa Kellokumpu-Lehtinen; Owen J Sansom; Gerard I Evan; Melissa R Junttila; Kevin M Ryan; Jean-Christophe Marine; Heikki Joensuu; Jukka Westermarck
Journal:  Cancer Discov       Date:  2013-01-10       Impact factor: 39.397
View more
  7 in total

1.  Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.

Authors:  Filip Rázga; Veronika Némethová
Journal:  Haematologica       Date:  2017-01       Impact factor: 9.941

2.  PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.

Authors:  Swagata Goswami; Rajeswaran Mani; Jessica Nunes; Chi-Ling Chiang; Kevan Zapolnik; Eileen Hu; Frank Frissora; Xiaokui Mo; Logan A Walker; Pearlly Yan; Ralf Bundschuh; Larry Beaver; Raymond Devine; Yo-Ting Tsai; Ann Ventura; Zhiliang Xie; Min Chen; Rosa Lapalombella; Alison Walker; Alice Mims; Karilyn Larkin; Nicole Grieselhuber; Chad Bennett; Mitch Phelps; Erin Hertlein; Gregory Behbehani; Sumithira Vasu; John C Byrd; Natarajan Muthusamy
Journal:  Blood       Date:  2022-03-03       Impact factor: 25.476

Review 3.  The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.

Authors:  Peter P Ruvolo
Journal:  BBA Clin       Date:  2016-08-03

Review 4.  Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.

Authors:  Elena Arriazu; Raffaella Pippa; María D Odero
Journal:  Front Oncol       Date:  2016-04-06       Impact factor: 6.244

5.  Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.

Authors:  Xuewen Liu; Wei Cao; Shanshan Qin; Te Zhang; Junnian Zheng; Ying Dong; Pinghong Ming; Qian Cheng; Zheng Lu; Yang Guo; Baofu Zhang; Ying Liu
Journal:  Signal Transduct Target Ther       Date:  2017-05-26

6.  Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.

Authors:  Eleonora Mäkelä; Eliisa Löyttyniemi; Urpu Salmenniemi; Otto Kauko; Taru Varila; Veli Kairisto; Maija Itälä-Remes; Jukka Westermarck
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

Review 7.  The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias.

Authors:  Raffaella Pippa; Maria D Odero
Journal:  Cells       Date:  2020-02-26       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.